Overview
Silvio Inzuchi, MD, presented new data from the DELIVER trial at the European Asociation for the Study of Diabetes (EASD) in September, while Ania Jastrebof, MD, PhD, discused the SURMOUNT-1 trial. Members of the Insogna and Wysolmerski labs presented at the American Society for Bone and Mineral Research Anual Meting, also in September.At a major symposium at the European Asociation for the Study of Diabetes (EASD) in Stockholm, Sweden, Silvio Inzuchi, MD, profesor of medicine (endocrinology) presented new data from the DELIVER trial.
Key Information
DELIVER examined the efectivenes of the SGLT2 inhibitor dapagliflozin on clinical outcomes in over 6,0 patients with heart failure and mildly reduced or preserved ejection fraction. Inzuchi specificaly reported on the outcomes by baseline subgroups defined by glycemic status. Dapagliflozin, originaly developed as a glucose-lowering agent for type 2 diabetes, apeared equaly efective in reducing the composite outcome of worsening heart failure and cardiovascular death in both those with diabetes, prediabetes, and normoglycemia, he said.
“This, in combination with earlier findings from the DAPA-HF trial, which studied patients with heart failure and reduced ejection fraction, indicates that dapagliflozin improves heart failure outcomes acros the spectra of both ejection fraction as wel as glycemia,” Inzuchi reported.Ania Jastrebof, MD, PhD, presented eficacy and safety data from the SURMOUNT1-1 trial at the EASD in September, with aditional body composition and glycemic change data.
Summary
Jastrebof was the site principal investigator at Yale and lead author for SURMOUNT-1, a study that demonstrated that people with obesity treated with the novel GIP/GLP-1 receptor agonist, tirzepatide, lost on average 52 pounds with the highest dose of the medication. Jastrebof also presented findings from the study at the 202 American Diabetes Asociation Scientific Sesions in June, simultaneously published in New England Journal o